The invention relates to new doses and regimens of rifapentine and use in the treatment of active tuberculosis disease or tuberculosis infection in patients infected with the human immunodeficiency virus (HIV) / acquired immune deficiency syndrome (AIDS) and treated with a combined antiretroviral combination, in particular with an efavirenz-based combination, and more particularly with a combination of efavirenz, emtricitabine and tenofovir disoproxil fumarate.

The invention relates to new doses and regimens of rifapentine and use in the prevention/treatment of active tuberculosis disease or tuberculosis infection in patients infected with the human immunodeficiency virus (HIV) / acquired immune deficiency syndrome (AIDS) and treated with a combined antiretroviral combination, a combination of efavirenz, emtricitabine and tenofovir disoproxil fumarate.

This invention relates to a process for the preparation of (R)-9-[2- (phosphonometh-oxy)propyl]adenine (PMPA). This invention also relates to the preparation of Tenofovir disoproxil fumarate (TDF), a compound which can be produced from PMPA. The claimed process comprises reacting compound (6) with compound (7) in presence of 2,2,6,6- tetramethylpiperidinylmagnesium to compound (2), which is hydrolysed to (3).

The present invention relates to a novel tenofovir disoproxil aspartate compound. The aforementioned salt compound allows minimal formation of related substances occurring with passage of time, increasing the stability of the formulation by drastically reducing the formation of impurities during storage. Also, the need for a separate study of toxicological effects is eliminated. Moreover, the salt compound of the present invention possesses superior physicochemical properties, with a significant...

The invention relates to a tenofovir prodrug and pharmaceutical uses thereof. In particular, the invention relates to a compound as shown in general formula (I) and its isomer, pharmaceutically acceptable salt, hydrate or solvate, as well as their uses in preparing drugs for treating viral infectious diseases, especially HIV infection, hepatitis B and diseases caused by hepatitis B virus, the definition of each substituent in the general formula (I) being the same as the definition in the specif...

Disclosed is a Tenofovir diester compound shown as a general formula (I), a salt or tautomer thereof,as well as a preparation method and use thereof and a pharmaceutical composition comprising the same. The compound has good liposolubility, and strong anti-HIV effect and anti-HBV effect.

In accordance with this invention a novel pharmaceutical product containing efavirenz emtricitabine and tenofovir DF are provided as a multicomponent unitary oral dosage form component 1 comprising tenofovir DF (and optionally emtricitabine) and component 2 comprising efavirenz wherein components 1 and 2 are in a stabilizing configuration. In preferred embodiments component 1 is made by dry granulation.